Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

Peter Kremsner, Philipp Mann, Jacobus Bosch, Rolf Fendel, Julian J. Gabor, Andrea Kreidenweiss, Arne Kroidl, Isabel Leroux-Roels, Geert Leroux-Roels, Christoph Schindler, Mirjam Schunk, Thirumalaisamy P. Velavan, Mariola Fotin-Mleczek, Stefan Müller, Gianluca Quintini, Oliver Schönborn-Kellenberger, Dominik Vahrenhorst, Thomas Verstraeten, Lisa Walz, Olaf-Oliver Wolz, Lidia Oostvogels
doi: https://doi.org/10.1101/2020.11.09.20228551
Peter Kremsner
1Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany
10German Center for Infection Research (DZIF), partner site Tübingen, Tübingen, Germany
11Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philipp Mann
6Curevac AG, Frankfurt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacobus Bosch
5Hannover Medical School (MHH), Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rolf Fendel
1Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julian J. Gabor
1Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Kreidenweiss
1Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arne Kroidl
3Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Germany
4German Center for Infection Research (DZIF), partner site Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabel Leroux-Roels
2Ghent University Hospital, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geert Leroux-Roels
2Ghent University Hospital, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Schindler
5Hannover Medical School (MHH), Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mirjam Schunk
3Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Germany
4German Center for Infection Research (DZIF), partner site Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thirumalaisamy P. Velavan
1Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariola Fotin-Mleczek
9Curevac AG, Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Müller
6Curevac AG, Frankfurt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gianluca Quintini
8Cogitars, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Schönborn-Kellenberger
8Cogitars, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominik Vahrenhorst
9Curevac AG, Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Verstraeten
7P95 Epidemiology and Pharmacovigilance, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Walz
6Curevac AG, Frankfurt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olaf-Oliver Wolz
9Curevac AG, Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lidia Oostvogels
6Curevac AG, Frankfurt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lidia.oostvogels@curevac.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

There is an urgent need for vaccines to counter the COVID-19 pandemic due to infections with severe acute respiratory syndrome coronavirus (SARS-CoV-2). Evidence from convalescent sera and preclinical studies has identified the viral Spike (S) protein as a key antigenic target for protective immune responses. We have applied an mRNA-based technology platform, RNActive®, to develop CVnCoV which contains sequence optimized mRNA coding for a stabilized form of S protein encapsulated in lipid nanoparticles (LNP). Following demonstration of protective immune responses against SARS-CoV-2 in animal models we performed a dose-escalation phase 1 study in healthy 18-60 year-old volunteers.

This interim analysis shows that two doses of CVnCoV ranging from 2 μg to 12 μg per dose, administered 28 days apart were safe. No vaccine-related serious adverse events were reported. There were dose-dependent increases in frequency and severity of solicited systemic adverse events, and to a lesser extent of local reactions, but the majority were mild or moderate and transient in duration. Immune responses when measured as IgG antibodies against S protein or its receptor-binding domain (RBD) by ELISA, and SARS-CoV-2-virus neutralizing antibodies measured by micro-neutralization, displayed dose-dependent increases. Median titers measured in these assays two weeks after the second 12 μg dose were comparable to the median titers observed in convalescent sera from COVID-19 patients. Seroconversion (defined as a 4-fold increase over baseline titer) of virus neutralizing antibodies two weeks after the second vaccination occurred in all participants who received 12 μg doses.

Preliminary results in the subset of subjects who were enrolled with known SARS-CoV-2 seropositivity at baseline show that CVnCoV is also safe and well tolerated in this population, and is able to boost the pre-existing immune response even at low dose levels.

Based on these results, the 12 μg dose is selected for further clinical investigation, including a phase 2b/3 study that will investigate the efficacy, safety, and immunogenicity of the candidate vaccine CVnCoV.

Competing Interest Statement

Philipp Mann, Mariola Fotin-Mleczek, Stefan Mueller, Gianluca Quintini, Dominik Vahrenhorst, Lisa Walz, Olaf-Oliver Wolz, Lidia Oostvogels are employees of CureVac AG Oliver Schoenborn-Kellenberger, Thomas Verstraeten received consultancy fees from CureVac AG

Clinical Trial

NCT04449276

Funding Statement

CureVac AG Friedrich-Miescher-Str. 15 72076 Tuebingen Germany

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

EC Tuebingen, Germany EC Gent, Belgium

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

No additional data are referred to

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted November 09, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers
Peter Kremsner, Philipp Mann, Jacobus Bosch, Rolf Fendel, Julian J. Gabor, Andrea Kreidenweiss, Arne Kroidl, Isabel Leroux-Roels, Geert Leroux-Roels, Christoph Schindler, Mirjam Schunk, Thirumalaisamy P. Velavan, Mariola Fotin-Mleczek, Stefan Müller, Gianluca Quintini, Oliver Schönborn-Kellenberger, Dominik Vahrenhorst, Thomas Verstraeten, Lisa Walz, Olaf-Oliver Wolz, Lidia Oostvogels
medRxiv 2020.11.09.20228551; doi: https://doi.org/10.1101/2020.11.09.20228551
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers
Peter Kremsner, Philipp Mann, Jacobus Bosch, Rolf Fendel, Julian J. Gabor, Andrea Kreidenweiss, Arne Kroidl, Isabel Leroux-Roels, Geert Leroux-Roels, Christoph Schindler, Mirjam Schunk, Thirumalaisamy P. Velavan, Mariola Fotin-Mleczek, Stefan Müller, Gianluca Quintini, Oliver Schönborn-Kellenberger, Dominik Vahrenhorst, Thomas Verstraeten, Lisa Walz, Olaf-Oliver Wolz, Lidia Oostvogels
medRxiv 2020.11.09.20228551; doi: https://doi.org/10.1101/2020.11.09.20228551

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (580)
  • Anesthesia (141)
  • Cardiovascular Medicine (1962)
  • Dentistry and Oral Medicine (253)
  • Dermatology (187)
  • Emergency Medicine (335)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (703)
  • Epidemiology (11123)
  • Forensic Medicine (8)
  • Gastroenterology (629)
  • Genetic and Genomic Medicine (3196)
  • Geriatric Medicine (310)
  • Health Economics (567)
  • Health Informatics (2049)
  • Health Policy (864)
  • Health Systems and Quality Improvement (789)
  • Hematology (310)
  • HIV/AIDS (685)
  • Infectious Diseases (except HIV/AIDS) (12742)
  • Intensive Care and Critical Care Medicine (708)
  • Medical Education (318)
  • Medical Ethics (92)
  • Nephrology (337)
  • Neurology (3004)
  • Nursing (165)
  • Nutrition (465)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1561)
  • Ophthalmology (478)
  • Orthopedics (186)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (403)
  • Pediatrics (914)
  • Pharmacology and Therapeutics (386)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2799)
  • Public and Global Health (5613)
  • Radiology and Imaging (1101)
  • Rehabilitation Medicine and Physical Therapy (637)
  • Respiratory Medicine (764)
  • Rheumatology (341)
  • Sexual and Reproductive Health (315)
  • Sports Medicine (289)
  • Surgery (348)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (133)